Levetiracetam for Painful Polyneuropathy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00286260 |
Recruitment Status :
Completed
First Posted : February 3, 2006
Last Update Posted : December 18, 2009
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Painful Polyneuropathy | Drug: levetiracetam | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 40 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Double-blind, Randomised, Placebo-controlled Trial of the Effect of Levetiracetam on Painful Polyneuropathy |
Study Start Date : | January 2006 |
Actual Primary Completion Date : | August 2008 |
Actual Study Completion Date : | October 2008 |

- Drug: levetiracetam
Levetiracetam tablet 500 mg, daily dose titrated to 3000 mg, 6 weeks
- Pain relief rated on a 0 to 10 point numeric rating scale (median value for last treatment week in each period) [ Time Frame: Daily ]
- Pain rated on 0 to 10 point numeric rating scales [ Time Frame: Daily ]
- Pain subtypes rated on 0 to 10 point numeric rating scales [ Time Frame: Daily ]
- Bruch-evoked pain [ Time Frame: Baseline and end of each treament period ]
- Pin-prick evoked pain [ Time Frame: Baseline and end of each treatment period ]
- Cold evoked pain [ Time Frame: Baseline and end of each treatment period ]
- Health related quality of life(SF-36) [ Time Frame: Baseline and end of each treatment period ]
- Pain related sleep disturbance [ Time Frame: Daily ]
- Use of escape medication [ Time Frame: Daily ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- age 20 to 0 years
- painful symptoms of polyneuropathy for at least 6 months
- confirmed diagnosis of polyneuropathy
- baseline pain score of 4 or more (0 to 10 point scale)
- pain at least 4 days a week
- adequate anticonceptive treatment for women with childbearing potential
- informed consent
Exclusion Criteria:
- other cause of pain
- previous allergic reactions towards levetiracetam
- known adverse drug reactions on levetiracetam
- pregnancy
- severe disease
- inability to follow study protocol
- treatment with antidepressants, other anticonvulsants or opioids

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00286260
Denmark | |
Department of Neurology, Odense University Hospital | |
Odense C, Denmark, DK-5000 |
Study Chair: | Søren H Sindrup, Professor | Department of Neurology, Odense Unviersity Hospital |
Responsible Party: | Professor Søren H. Sindrup, Odense University Hospital |
ClinicalTrials.gov Identifier: | NCT00286260 |
Other Study ID Numbers: |
keppra2 |
First Posted: | February 3, 2006 Key Record Dates |
Last Update Posted: | December 18, 2009 |
Last Verified: | January 2006 |
polyneuropathy neuropathic pain levetiracetam |
Polyneuropathies Pain Neurologic Manifestations Peripheral Nervous System Diseases Neuromuscular Diseases |
Nervous System Diseases Levetiracetam Anticonvulsants Nootropic Agents |